
Zydus Lifesciences Limited has announced an increase in its buyback price to ₹1,260 per share. This adjustment follows a prior announcement and involves a reduction in the total number of shares to be bought back.
On May 27, 2026, Zydus Lifesciences disclosed an increase in the buyback price from ₹1,150 to ₹1,260 per share.
This decision was made to adjust the buyback strategy, resulting in a reduction of the maximum number of shares to be repurchased.
The new total stands at 87,30,158 shares, down from the initially planned 95,65,217 shares. This buyback represents up to 0.87% of the company's total paid-up share capital.
The buyback is being conducted in accordance with the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended.
The initial public announcement was made on May 20, 2026, and published the following day. The company has since issued an addendum to update stakeholders on the revised buyback price and share count.
The increase in the buyback price is a strategic move by Zydus Lifesciences to provide better value to its shareholders.
By reducing the number of shares to be repurchased, the company aims to maintain a balanced approach to capital allocation while enhancing shareholder returns.
Read More: Wipro Fixes June 5, 2026, as Record Date for ₹15,000 Crore Shares Buyback Offer!
As of May 29, 2026, at 11:03 AM, Zydus Lifesciences share price on NSE was trading at ₹1,098.00 up by 1.12% from the previous closing price.
Zydus Lifesciences' decision to raise the buyback price to ₹1,260 per share and adjust the number of shares involved reflects a calculated approach to managing its equity structure. This move aligns with regulatory requirements and aims to benefit shareholders by offering an increased buyback value.
For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: May 29, 2026, 12:03 PM IST

Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
